<DOC>
	<DOCNO>NCT01818856</DOCNO>
	<brief_summary>Hypothesis : Telaprevir ( TVR ) plasma level ( 750 mg q8h 1125 mg/12h ) affect co-administered un-boosted Atazanavir ( ATV ) 200 mg q12h plus two analogue ( NRTIs ) HCV/HIV-co-infected patient .</brief_summary>
	<brief_title>Pharmacokinetic Interactions Between Telaprevir Un-boosted Atazanavir</brief_title>
	<detailed_description>Objectives 1 . Primary Outcome Measures : evaluate change plasma pharmacokinetic parameter ( Cmax , Cmin , AUC , 1/2 , Cl ) Telaprevir ( TVR ) administer 750 mg/8h together un-boosted Atazanavir ( 200 mg/12h ) , take reference pharmacokinetic parameter observe TVR administer Atazanavir/ritonavir ( 300/100 mg/day ) 2 . To assess change plasma pharmacokinetic parameter Atazanavir administer 200 mg/12h respect administration 300/100 mg/day administer together TVR ( 750 mg/8h 1125 mh/12h ) . Method : open label clinical trial plan duration 24 week 14 HIV/Hepatitis C virus genotype 1 patient treatment pegylated α-interferon , Ribavirin Telaprevir enrol . A 24 hour pharmacokinetic profile obtain supervised drug intake take TVR ATV/rtv . Afterwards , patient take un-boosted ATV 200 mg bid 7 - 10 day . Subsequently , new pharmacokinetic profile obtain .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Patients 18 year old coinfected HIV genotype 1 HCV treatment pegylated αinterferon , Ribavirin Telaprevir accord recommendation Spanish Agency Medicines Health Products . Informed consent patient . The usual exclusion criterion clinical practice start treatment drug ( pegylated αinterferon , Ribavirin , Telaprevir atazanavir ) accord Spanish international recommendation ( Spanish Agency Medicines Health Products , European Association Study Liver Clinical Practice Guidelines : management hepatitis C virus infection . J Hepatol . 2011 . Consensus Document Gesida/Spanish Plan Aids regard antiretroviral treatment adult infect human immunodeficiency virus [ Updated January 2012 ] ) . Concomitant use drug medicinal product could alter pharmacokinetics TVR ATV . Medical record suggest malabsorption presence diarrhea ( &gt; 3 depositions/day ) could interfere absorption study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>HIV-infection</keyword>
	<keyword>Drug interaction</keyword>
</DOC>